中国药理学通报2017，Vol.33Issue(6)：772-780,9.DOI:10.3969/j.issn.1001-1978.2017.06.008
黄连素和吴茱萸碱协同抗癌的miRNA网络机制研究
Study of synergistic mechanism in the combination ofberberine and evodiamine from the perspective of miRNA
摘要
Abstract
Aim To explore the mechanisms of action (MOA) of synergistic anticancer function in the combination of berberine and evodiamine.Methods We first analyzed the action of suppression in the drug combination from the cell level and validated the dose scope as well as ratio of concentration in synergistic effects of drug combination.Then, the miRNA chip of liver cancer cell BEL-7402 under different treatment was analyzed.By building the miRNA-mRNA network, the MOA of the synergistic drug combination was illustrated.Results Berberine and evodiamine used in combination could significantly synergistically suppress the proliferative ability of liver cancer cells.The special differentially expressed miRNAs (DEmiRNAs) mainly participated in some cancer proliferation-related pathways and biological processes, such as MAPK signaling pathway, endocytosis pathway and insulin signaling pathway.The special target genes influenced by the drug combination not only covered three kinds of membrane receptors, but also took part in the regulation of downstream pathways.Conclusions From the regulation of miRNAs, it is clear that berberine may play a primary role in the synergistical suppression activity of the drug combination in cancer cells.The discovery of synergistic MOA in the combination of berberine and evodiamine from the miRNA level will provide a new guidance to explore more synergistic drug combinations in the future.关键词
黄连素/吴茱萸碱/联合用药/协同用药/作用机制/KEGG通路/通路网络Key words
berberine/evodiamine/drug combination/synergistic drug combination/mechanisms of action/KEGG pathway/pathway network分类
医药卫生引用本文复制引用
尹作静,曹志伟,闫鑫淼,阳奕琰,盛振..黄连素和吴茱萸碱协同抗癌的miRNA网络机制研究[J].中国药理学通报,2017,33(6):772-780,9.基金项目
国家高等科技研究与发展基金(863项目)资助项目(No 2012AA020405) （863项目）
卫生部资助基金项目(No 2012ZX10005001) （No 2012ZX10005001）
